Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06356129




Registration number
NCT06356129
Ethics application status
Date submitted
27/03/2024
Date registered
10/04/2024
Date last updated
21/06/2024

Titles & IDs
Public title
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Scientific title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)
Secondary ID [1] 0 0
2023-510178-15
Secondary ID [2] 0 0
CA073-1020
Universal Trial Number (UTN)
Trial acronym
GOLSEEK-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Large B-cell Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Golcadomide
Treatment: Drugs - Placebo
Treatment: Drugs - Rituximab
Treatment: Drugs - Cyclophosphamide
Treatment: Drugs - Doxorubicin
Treatment: Drugs - Vincristine
Treatment: Drugs - Prednisone

Experimental: Golcadomide + R-CHOP (Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone) -

Placebo comparator: Placebo + R-CHOP -


Treatment: Drugs: Golcadomide
Specified dose on specified days

Treatment: Drugs: Placebo
Specified dose on specified days

Treatment: Drugs: Rituximab
Specified dose on specified days

Treatment: Drugs: Cyclophosphamide
Specified dose on specified days

Treatment: Drugs: Doxorubicin
Specified dose on specified days

Treatment: Drugs: Vincristine
Specified dose on specified days

Treatment: Drugs: Prednisone
Specified dose on specified days
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free survival (PFS) assessed by the Investigator
Timepoint [1] 0 0
Up to approximately 67 months
Secondary outcome [1] 0 0
Overall survival (OS)
Timepoint [1] 0 0
Up to approximately 67 months
Secondary outcome [2] 0 0
Event-free survival (EFS)
Timepoint [2] 0 0
Up to approximately 67 months
Secondary outcome [3] 0 0
Complete Metabolic Response assessed by the Independent Response Adjudication Committee (IRAC)
Timepoint [3] 0 0
Up to approximately 18 weeks
Secondary outcome [4] 0 0
Minimal residual disease (MRD) negativity rate
Timepoint [4] 0 0
Up to approximately 18 weeks
Secondary outcome [5] 0 0
Progression-free survival (PFS) assessed by the IRAC
Timepoint [5] 0 0
Up to approximately 47 months
Secondary outcome [6] 0 0
Objective response (OR) assessed by the Investigator
Timepoint [6] 0 0
Up to approximately 18 weeks
Secondary outcome [7] 0 0
Complete metabolic response (CMR) assessed by the Investigator
Timepoint [7] 0 0
Up to approximately 18 weeks
Secondary outcome [8] 0 0
PFS24 assessed by the Investigator 24 months after randomization
Timepoint [8] 0 0
Up to 24 months
Secondary outcome [9] 0 0
Duration of response (DoR)
Timepoint [9] 0 0
Up to approximately 67 months
Secondary outcome [10] 0 0
Second progression-free survival (PFS2) assessed by the Investigator
Timepoint [10] 0 0
Up to approximately 67 months
Secondary outcome [11] 0 0
Relative dose intensity (%)
Timepoint [11] 0 0
Up to 18 weeks
Secondary outcome [12] 0 0
Time from randomization to meaningful improvement in primary domains of interest in the European Organization for Research and Treatment of Cancer - Quality of Life C30 (EORTC QLQ-C30) Questionnaire
Timepoint [12] 0 0
Up to approximately 67 months
Secondary outcome [13] 0 0
Time from randomization to meaningful improvement in primary domains of interest in the Functional Assessment of Cancer Treatment-Lymphoma (FACT-LymS) Questionnaire
Timepoint [13] 0 0
Up to approximately 67 months
Secondary outcome [14] 0 0
Mean change from baseline in the EORTC QLQ-C30
Timepoint [14] 0 0
Up to approximately 67 months
Secondary outcome [15] 0 0
Mean change from baseline in the FACT-LymS
Timepoint [15] 0 0
Up to approximately 67 months
Secondary outcome [16] 0 0
Number of participants with Adverse Events (AEs)
Timepoint [16] 0 0
Up to approximately 20 weeks
Secondary outcome [17] 0 0
Number of participants with treatment-emergent adverse events (TEAEs)
Timepoint [17] 0 0
Up to approximately 20 weeks
Secondary outcome [18] 0 0
Number of participants with laboratory abnormalities
Timepoint [18] 0 0
Up to approximately 20 weeks
Secondary outcome [19] 0 0
Number of participants with vital sign abnormalities
Timepoint [19] 0 0
Up to approximately 20 weeks

Eligibility
Key inclusion criteria
- Histologically confirmed (per local evaluation) diagnosis of de novo, previously untreated large B-cell lymphoma (LBCL) according to 2022 world health organization (WHO) classification including:

i) Diffuse large B-cell lymphoma (DLBCL), not otherwise specified [including germinal center B-cell (GCB) and activated B-cell (ABC) types]

ii) High-grade B-cell lymphoma, with MYC and BCL2 rearrangements

iii) High-grade B-cell lymphoma, not otherwise specified

iv) T-cell/histiocyte/rich large B-cell lymphoma (THRLBCL)

v) Epstein-Barr virus + DLBCL

* International Prognostic Index (IPI) score 1 or 2 with lactate dehydrogenase (LDH) = 1.3 x upper limit of normal (ULN) and/or bulky disease defined as single lesion of = 7 cm OR IPI = 3.
* Measurable disease defined by at least 1 fluorodeoxyglucose (FDG)-avid lesion for FDG-avid subtype and 1 bi-dimensionally measurable (> 1.5 cm in longest diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification.
* Must have Ann Arbor Stage II-IV disease.
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Any significant medical condition, active infection, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.
* Any other subtype of lymphoma. Cases of primary mediastinal (thymic) large B-cell lymphoma (PMBCL), primary cutaneous DLBCL-leg type, Grade 3b FL, FL transformed to a-BCL, Anaplastic lymphoma kinase (ALK) positive large B-cell lymphoma, primary effusion lymphoma, and Burkitt lymphoma.
* Documented or suspected central nervous system (CNS) involvement by lymphoma.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
24/06/2024
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
20/11/2029
Actual
Sample size
Target
850
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,NT,QLD,VIC
Recruitment hospital [1] 0 0
Local Institution - 0357 - Gosford
Recruitment hospital [2] 0 0
Local Institution - 0361 - Sydney
Recruitment hospital [3] 0 0
Local Institution - 0358 - Westmead
Recruitment hospital [4] 0 0
Local Institution - 0363 - Tiwi
Recruitment hospital [5] 0 0
Local Institution - 0356 - Birtinya
Recruitment hospital [6] 0 0
Local Institution - 0360 - Southport
Recruitment hospital [7] 0 0
Peninsula Private Hospital - Frankston
Recruitment hospital [8] 0 0
Local Institution - 0362 - Heidelberg
Recruitment hospital [9] 0 0
Local Institution - 0359 - St Albans
Recruitment hospital [10] 0 0
Local Institution - 0364 - Warrnambool
Recruitment postcode(s) [1] 0 0
2250 - Gosford
Recruitment postcode(s) [2] 0 0
2560 - Sydney
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
0810 - Tiwi
Recruitment postcode(s) [5] 0 0
4575 - Birtinya
Recruitment postcode(s) [6] 0 0
4215 - Southport
Recruitment postcode(s) [7] 0 0
3195 - Frankston
Recruitment postcode(s) [8] 0 0
3084 - Heidelberg
Recruitment postcode(s) [9] 0 0
3021 - St Albans
Recruitment postcode(s) [10] 0 0
3280 - Warrnambool
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Iowa
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
Kentucky
Country [10] 0 0
United States of America
State/province [10] 0 0
Louisiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Nevada
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oklahoma
Country [19] 0 0
United States of America
State/province [19] 0 0
Oregon
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Virginia
Country [23] 0 0
Argentina
State/province [23] 0 0
Ciudad Autónoma De Buenos Aires
Country [24] 0 0
Argentina
State/province [24] 0 0
Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Ciudad Autónoma de Buenos Aires
Country [26] 0 0
Argentina
State/province [26] 0 0
Córdoba
Country [27] 0 0
Austria
State/province [27] 0 0
Oberösterreich
Country [28] 0 0
Austria
State/province [28] 0 0
Linz
Country [29] 0 0
Austria
State/province [29] 0 0
Vienna
Country [30] 0 0
Brazil
State/province [30] 0 0
Ceará
Country [31] 0 0
Brazil
State/province [31] 0 0
Distrito Federal
Country [32] 0 0
Brazil
State/province [32] 0 0
Goiás
Country [33] 0 0
Brazil
State/province [33] 0 0
Paraná
Country [34] 0 0
Brazil
State/province [34] 0 0
Rio De Janeiro
Country [35] 0 0
Brazil
State/province [35] 0 0
Rio Grande Do Norte
Country [36] 0 0
Brazil
State/province [36] 0 0
Rio Grande Do Sul
Country [37] 0 0
Brazil
State/province [37] 0 0
Santa Catarina
Country [38] 0 0
Brazil
State/province [38] 0 0
São Paulo
Country [39] 0 0
Brazil
State/province [39] 0 0
Rio de Janeiro
Country [40] 0 0
Bulgaria
State/province [40] 0 0
Sofia (stolitsa)
Country [41] 0 0
Bulgaria
State/province [41] 0 0
Plovdiv
Country [42] 0 0
Bulgaria
State/province [42] 0 0
Sofia
Country [43] 0 0
Canada
State/province [43] 0 0
British Columbia
Country [44] 0 0
Canada
State/province [44] 0 0
Quebec
Country [45] 0 0
Chile
State/province [45] 0 0
Región Metropolitana De Santiago
Country [46] 0 0
Chile
State/province [46] 0 0
Valparaíso
Country [47] 0 0
China
State/province [47] 0 0
Beijing
Country [48] 0 0
China
State/province [48] 0 0
Chongqing
Country [49] 0 0
China
State/province [49] 0 0
Fujian
Country [50] 0 0
China
State/province [50] 0 0
Guangdong
Country [51] 0 0
China
State/province [51] 0 0
Guangxi
Country [52] 0 0
China
State/province [52] 0 0
Heilongjiang
Country [53] 0 0
China
State/province [53] 0 0
Henan
Country [54] 0 0
China
State/province [54] 0 0
Hubei
Country [55] 0 0
China
State/province [55] 0 0
Hunan
Country [56] 0 0
China
State/province [56] 0 0
Jiangsu
Country [57] 0 0
China
State/province [57] 0 0
Jiangxi
Country [58] 0 0
China
State/province [58] 0 0
Jilin
Country [59] 0 0
China
State/province [59] 0 0
Liaoning
Country [60] 0 0
China
State/province [60] 0 0
Shandong
Country [61] 0 0
China
State/province [61] 0 0
Shanghai
Country [62] 0 0
China
State/province [62] 0 0
Shanxi
Country [63] 0 0
China
State/province [63] 0 0
Sichuan
Country [64] 0 0
China
State/province [64] 0 0
Tianjin
Country [65] 0 0
China
State/province [65] 0 0
Xinjiang
Country [66] 0 0
China
State/province [66] 0 0
Zhejiang
Country [67] 0 0
Colombia
State/province [67] 0 0
Cundinamarca
Country [68] 0 0
Colombia
State/province [68] 0 0
Distrito Capital De Bogotá
Country [69] 0 0
Croatia
State/province [69] 0 0
Grad Zagreb
Country [70] 0 0
Croatia
State/province [70] 0 0
Osijek
Country [71] 0 0
Czechia
State/province [71] 0 0
Brno-mesto
Country [72] 0 0
Czechia
State/province [72] 0 0
Hradec Králové
Country [73] 0 0
Czechia
State/province [73] 0 0
Olomoucký Kraj
Country [74] 0 0
Czechia
State/province [74] 0 0
Plzenský Kraj
Country [75] 0 0
Czechia
State/province [75] 0 0
Praha 10
Country [76] 0 0
Czechia
State/province [76] 0 0
Praha 2
Country [77] 0 0
Denmark
State/province [77] 0 0
Midtjylland
Country [78] 0 0
Denmark
State/province [78] 0 0
Syddanmark
Country [79] 0 0
Finland
State/province [79] 0 0
Pohjois-Pohjanmaa
Country [80] 0 0
Finland
State/province [80] 0 0
Pohjois-Savo
Country [81] 0 0
Finland
State/province [81] 0 0
Varsinais-Suomi
Country [82] 0 0
Finland
State/province [82] 0 0
Helsinki
Country [83] 0 0
France
State/province [83] 0 0
Alpes-Maritimes
Country [84] 0 0
France
State/province [84] 0 0
Alsace
Country [85] 0 0
France
State/province [85] 0 0
Aquitaine
Country [86] 0 0
France
State/province [86] 0 0
Bouches-du-Rhône
Country [87] 0 0
France
State/province [87] 0 0
Côte-d'Or
Country [88] 0 0
France
State/province [88] 0 0
Finistère
Country [89] 0 0
France
State/province [89] 0 0
Hauts-de-Seine
Country [90] 0 0
France
State/province [90] 0 0
Indre-et-Loire
Country [91] 0 0
France
State/province [91] 0 0
La Réunion
Country [92] 0 0
France
State/province [92] 0 0
Loire
Country [93] 0 0
France
State/province [93] 0 0
Nord
Country [94] 0 0
France
State/province [94] 0 0
Pays-de-la-Loire
Country [95] 0 0
France
State/province [95] 0 0
Rhône
Country [96] 0 0
France
State/province [96] 0 0
Val-de-Marne
Country [97] 0 0
France
State/province [97] 0 0
Vienne
Country [98] 0 0
France
State/province [98] 0 0
Bayonne
Country [99] 0 0
France
State/province [99] 0 0
Caen
Country [100] 0 0
France
State/province [100] 0 0
Lille
Country [101] 0 0
France
State/province [101] 0 0
Paris
Country [102] 0 0
Germany
State/province [102] 0 0
Bayern
Country [103] 0 0
Germany
State/province [103] 0 0
Rheinland-Pfalz
Country [104] 0 0
Germany
State/province [104] 0 0
Essen
Country [105] 0 0
Greece
State/province [105] 0 0
Attikí
Country [106] 0 0
Greece
State/province [106] 0 0
Alexandroupolis
Country [107] 0 0
Greece
State/province [107] 0 0
Ípeiros
Country [108] 0 0
Hungary
State/province [108] 0 0
Pest
Country [109] 0 0
Hungary
State/province [109] 0 0
Somogy
Country [110] 0 0
Hungary
State/province [110] 0 0
Szabolcs-Szatmár-Bereg
Country [111] 0 0
Hungary
State/province [111] 0 0
Vas
Country [112] 0 0
Hungary
State/province [112] 0 0
Budapest
Country [113] 0 0
Hungary
State/province [113] 0 0
Debrecen
Country [114] 0 0
India
State/province [114] 0 0
Delhi
Country [115] 0 0
Japan
State/province [115] 0 0
Aichi
Country [116] 0 0
Japan
State/province [116] 0 0
Chiba
Country [117] 0 0
Japan
State/province [117] 0 0
Fukui
Country [118] 0 0
Japan
State/province [118] 0 0
Gifu
Country [119] 0 0
Japan
State/province [119] 0 0
Hokkaido
Country [120] 0 0
Japan
State/province [120] 0 0
Hyogo
Country [121] 0 0
Japan
State/province [121] 0 0
Ishikawa
Country [122] 0 0
Japan
State/province [122] 0 0
Iwate
Country [123] 0 0
Japan
State/province [123] 0 0
Kanagawa
Country [124] 0 0
Japan
State/province [124] 0 0
Miyagi
Country [125] 0 0
Japan
State/province [125] 0 0
Osaka
Country [126] 0 0
Japan
State/province [126] 0 0
Saitama
Country [127] 0 0
Japan
State/province [127] 0 0
Shizuoka
Country [128] 0 0
Japan
State/province [128] 0 0
Tokyo
Country [129] 0 0
Japan
State/province [129] 0 0
Yamanashi
Country [130] 0 0
Japan
State/province [130] 0 0
Fukuoka
Country [131] 0 0
Japan
State/province [131] 0 0
Hiroshima
Country [132] 0 0
Japan
State/province [132] 0 0
Kumamoto
Country [133] 0 0
Japan
State/province [133] 0 0
Kyoto
Country [134] 0 0
Japan
State/province [134] 0 0
Okayama
Country [135] 0 0
Japan
State/province [135] 0 0
Yamagata
Country [136] 0 0
Korea, Republic of
State/province [136] 0 0
Kyonggi-do
Country [137] 0 0
Korea, Republic of
State/province [137] 0 0
Pusan-Kwangyokshi
Country [138] 0 0
Korea, Republic of
State/province [138] 0 0
Seoul-teukbyeolsi [Seoul]
Country [139] 0 0
Korea, Republic of
State/province [139] 0 0
Taegu-Kwangyokshi
Country [140] 0 0
Korea, Republic of
State/province [140] 0 0
Seongnam
Country [141] 0 0
Malaysia
State/province [141] 0 0
Pulau Pinang
Country [142] 0 0
Malaysia
State/province [142] 0 0
Sarawak
Country [143] 0 0
Mexico
State/province [143] 0 0
Distrito Federal
Country [144] 0 0
Mexico
State/province [144] 0 0
Michoacán
Country [145] 0 0
Mexico
State/province [145] 0 0
Nuevo León
Country [146] 0 0
Mexico
State/province [146] 0 0
Oaxaca
Country [147] 0 0
Mexico
State/province [147] 0 0
Sonora
Country [148] 0 0
Mexico
State/province [148] 0 0
Huixquilucan
Country [149] 0 0
Mexico
State/province [149] 0 0
Puebla
Country [150] 0 0
New Zealand
State/province [150] 0 0
Otago
Country [151] 0 0
New Zealand
State/province [151] 0 0
Waikato
Country [152] 0 0
New Zealand
State/province [152] 0 0
Auckland
Country [153] 0 0
Norway
State/province [153] 0 0
Oslo
Country [154] 0 0
Poland
State/province [154] 0 0
Kujawsko-pomorskie
Country [155] 0 0
Poland
State/province [155] 0 0
Lubelskie
Country [156] 0 0
Poland
State/province [156] 0 0
Mazowieckie
Country [157] 0 0
Poland
State/province [157] 0 0
Malopolskie
Country [158] 0 0
Poland
State/province [158] 0 0
Wielkopolskie
Country [159] 0 0
Poland
State/province [159] 0 0
Slaskie
Country [160] 0 0
Portugal
State/province [160] 0 0
Lisboa
Country [161] 0 0
Portugal
State/province [161] 0 0
Porto
Country [162] 0 0
Puerto Rico
State/province [162] 0 0
San Juan
Country [163] 0 0
Romania
State/province [163] 0 0
Bucure?ti
Country [164] 0 0
Romania
State/province [164] 0 0
Mure?
Country [165] 0 0
Romania
State/province [165] 0 0
Brasov
Country [166] 0 0
Romania
State/province [166] 0 0
Cluj
Country [167] 0 0
Romania
State/province [167] 0 0
Ia?i
Country [168] 0 0
Romania
State/province [168] 0 0
Sibiu
Country [169] 0 0
Saudi Arabia
State/province [169] 0 0
Ash Sharqiyah
Country [170] 0 0
Saudi Arabia
State/province [170] 0 0
Riyadh
Country [171] 0 0
Singapore
State/province [171] 0 0
Central Singapore
Country [172] 0 0
Slovakia
State/province [172] 0 0
Banskobystrický Kraj
Country [173] 0 0
Slovakia
State/province [173] 0 0
Bratislava
Country [174] 0 0
Spain
State/province [174] 0 0
A Coruña [La Coruña]
Country [175] 0 0
Spain
State/province [175] 0 0
Barcelona [Barcelona]
Country [176] 0 0
Spain
State/province [176] 0 0
Bizkaia
Country [177] 0 0
Spain
State/province [177] 0 0
Canarias
Country [178] 0 0
Spain
State/province [178] 0 0
Gipuzkoa
Country [179] 0 0
Spain
State/province [179] 0 0
Madrid, Comunidad De
Country [180] 0 0
Spain
State/province [180] 0 0
Murcia, Región De
Country [181] 0 0
Spain
State/province [181] 0 0
Málaga
Country [182] 0 0
Spain
State/province [182] 0 0
Cáceres
Country [183] 0 0
Spain
State/province [183] 0 0
Madrid
Country [184] 0 0
Spain
State/province [184] 0 0
Salamanca
Country [185] 0 0
Sweden
State/province [185] 0 0
Uppsala Län [se-03]
Country [186] 0 0
Sweden
State/province [186] 0 0
Östergötlands Län [se-05]
Country [187] 0 0
Taiwan
State/province [187] 0 0
Chiayi
Country [188] 0 0
Taiwan
State/province [188] 0 0
Tainan
Country [189] 0 0
Taiwan
State/province [189] 0 0
Kaohsiung
Country [190] 0 0
Taiwan
State/province [190] 0 0
Taichung
Country [191] 0 0
Taiwan
State/province [191] 0 0
Taipei
Country [192] 0 0
Taiwan
State/province [192] 0 0
Taoyuan
Country [193] 0 0
Thailand
State/province [193] 0 0
Krung Thep Maha Nakhon
Country [194] 0 0
Thailand
State/province [194] 0 0
Chiang Mai
Country [195] 0 0
Turkey
State/province [195] 0 0
Ankara
Country [196] 0 0
Turkey
State/province [196] 0 0
Izmir
Country [197] 0 0
Turkey
State/province [197] 0 0
Mersin
Country [198] 0 0
Turkey
State/province [198] 0 0
Samsun
Country [199] 0 0
Turkey
State/province [199] 0 0
Trabzon

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Celgene
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma (LBCL).
Trial website
https://clinicaltrials.gov/study/NCT06356129
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Address 0 0
Country 0 0
Phone 0 0
855-907-3286
Fax 0 0
Email 0 0
Clinical.Trials@bms.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT06356129